About Takeda Pharmaceuticals
Takeda Pharmaceuticals is a Healthcare company based in Boston (United States) founded in 2014, and was acquired by Takeda in March 2021. T-cell-based antibody therapies for cancer are developed. It operates on a Direct-to-Consumer (D2C) and Professional Services model. Takeda Pharmaceuticals has raised $56 million across 1 funding round from investors including Takeda Pharmaceuticals. Takeda Pharmaceuticals offers products and services including Gastrointestinal and Inflammation Treatments, Rare Diseases Therapies, Plasma-Derived Therapies, Oncology Treatments, and Neuroscience Innovations. Its focus areas include Pharmaceuticals and Biopharmaceuticals. Its legal entity is Takeda Pharmaceutical Company Limited. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Takeda Pharmaceuticals is focused on the research and development of transformative medicines across various therapeutic areas. Specializations include gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Operations span multiple countries, addressing unmet medical needs through innovative solutions. Sustainability and corporate responsibility are integrated into the business strategy, with initiatives aimed at climate-resilient health systems. The company is committed to improving health outcomes and creating a brighter future for patients worldwide.
- Headquarters Boston, United States
- Stage Acquired
- SectorsHealthcare
- Website mavericktx.com
- Social LinkedIn YouTube
- Acquired by Takeda (Mar 2021)
- Legal Name Takeda Pharmaceutical Company Limited
- Total Equity Funding$56M (USD)
in 1 rounds
- Latest Funding Round$56M (USD), Series C
Jan 2017
- Investors
- Acquired byTakeda
(Mar 2021)
Products & Services of Takeda Pharmaceuticals
Takeda Pharmaceuticals offers a comprehensive portfolio of products and services, including Gastrointestinal and Inflammation Treatments, Rare Diseases Therapies, Plasma-Derived Therapies, Oncology Treatments, and Neuroscience Innovations.
Treatments for gastrointestinal and inflammatory diseases are developed.
Therapies for rare diseases in immunology are provided.
Innovative plasma therapies for chronic diseases are offered.
Cancer treatments inspired by patients are being developed.
Medical innovations for neurological diseases are being advanced.
Apps and channels of Takeda Pharmaceuticals
its YouTube channel Takeda has 23.6K subscribers and 30 videos.
Videos from Takeda Pharmaceuticals
The most watched videos on Takeda Pharmaceuticals's YouTube channel, Takeda (23.6K subscribers). Click a video to play it here.
More on Takeda.
Funding Insights of Takeda Pharmaceuticals
Takeda Pharmaceuticals has successfully raised a total of $56M through 1 strategic funding round. The most recent funding activity was a Series C round of $56 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $56M
- Total Rounds 1
- Last Round Series C — $56M
- First Round $56M
(Jan 2017)
All 1 funding rounds of Takeda Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2017 | $56M | Series C | – | – | – |
1 investors in total: 1 institutional.
Investors in Takeda Pharmaceuticals
Takeda Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Takeda Pharmaceuticals is engaged in developing innovative medicines globally. | 1781 | takeda.com | Tokyo, Japan |
Investor details for Takeda Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Takeda Pharmaceuticals
1 people are tracked at Takeda Pharmaceuticals (1 in leadership).
| Name | Role | Group |
|---|---|---|
James S. Scibetta | CEO | Leadership |
Complete people profiles for Takeda Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Takeda Pharmaceuticals
3 dated milestones of Takeda Pharmaceuticals across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Takeda Pharmaceuticals is founded.
- Funding First funding round of $56.0M.
- Exit Acquired by Takeda.
Competitors of Takeda Pharmaceuticals
Takeda Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Takeda Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Takeda Pharmaceuticals (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Takeda Pharmaceuticals
Complete news archive for Takeda Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Takeda Pharmaceuticals
Takeda Pharmaceuticals was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Takeda Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Takeda Pharmaceuticals is a funded company, having raised a total of $56M across 1 funding round to date. The company's 1st funding round was a Series C of $56M, raised on Jan 2017.
Takeda Pharmaceuticals is focused on the research and development of transformative medicines across various therapeutic areas. Specializations include gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Operations span multiple countries, addressing unmet medical needs through innovative solutions. Sustainability and corporate responsibility are integrated into the business strategy, with initiatives aimed at climate-resilient health systems. The company is committed to improving health outcomes and creating a brighter future for patients worldwide.
Takeda Pharmaceuticals offers Gastrointestinal and Inflammation Treatments, Rare Diseases Therapies, Plasma-Derived Therapies, Oncology Treatments, and Neuroscience Innovations.
Takeda Pharmaceuticals has 1 investor. Key investors include Takeda Pharmaceuticals.
Takeda Pharmaceuticals operates through Takeda Pharmaceutical Company Limited.
Yes. Takeda Pharmaceuticals was acquired by Takeda in March 2021.